why should autologous transplant remain the soc in myeloma?
Published 1 year ago • 38 plays • Length 0:43Download video MP4
Download video MP3
Similar videos
-
2:10
phase ii study of epd maintenance after second autologous transplant for multiple myeloma
-
1:48
the role of autologous transplantation in young and fit patients with multiple myeloma in 2022
-
2:28
is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
-
1:57
the benefit of double autologous transplantation in multiple myeloma patient subgroups
-
2:22
the benefit of autologous transplantation in the era of novel agents in multiple myeloma
-
1:58
with new treatment options in myeloma, is auto-sct still necessary?
-
2:48
can car-t therapy be used in conjunction with or instead of autologous transplantation in myeloma?
-
4:13
benefit trial: isatuximab, lenalidomide, and dexamethasone /- bortezomib in newly diagnosed myeloma
-
2:49
the importance of timing in autologous transplantation for multiple myeloma
-
1:53
transplantation for consolidation in multiple myeloma
-
1:50
the role of autologous transplant in aml
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
3:06
the importance of autologous transplantation in the era of immunotherapy
-
0:59
is car-t therapy going to replace stem cell transplantation in myeloma in the next five years?
-
1:22
the potential use of car-t therapy following autologous transplantation in multiple myeloma
-
1:43
feasibility of double autologous stem cell transplantation in patients with al amyloidosis
-
4:44
what are the advantages of multiple myeloma maintenance therapy?
-
1:01
car-t: myeloma toxicities